Method and devices for tissue expansion

ABSTRACT

A device for maintaining or achieving soft tissue expansion applicable to any body region already temporarily expanded including: an adhesive element deformable and capable of adapting to the shape of this body region, and which can then itself become mechanically rigid enough to resist tendency of the expanded tissue to recoil or to which a second material can be applied to form a stent adapted to the shape of the body area to provide the necessary structural rigidity to prevent recoil of the expansion and thereby induce its retention of its expanded shape after the stent is removed.

BACKGROUND AND SUMMARY OF THE INVENTION

Despite great strides in cell culture technology and in the medicalprofession's ability to isolate stem cells and manipulate them todifferentiate into various cell types, accomplishments in the field oftissue engineering solid organs remain limited.

This is because in addition to being a collection of specialized cells,a functional tissue engineered organ is generally thought to necessarilybe capable to fulfill the following requirements:

1. Contain a scaffold within which the cells reside and organizethemselves in the specific three dimensional architectural arrangementrequired for the organ to function. This scaffold is known in the art asthe stromal component of the tissue.

2. Ensure that each individual cell in the organ remains within veryclose proximity to a capillary blood vessel that can supply it with thenecessary nutrients. For this to happen, the construct needs to have adense three-dimensional vascular network of blood vessels andcapillaries.

3. Be able to connect this capillary network to the systemiccirculation.

These three requirements constitute what is known in the art as the“Holy Grail” of tissue engineering. However, building in the laboratorya stromal scaffold with a functional capillary circulation connected tothe arterial and venous circulation of the recipient remains an elusivegoal.

Without a functional internal capillary network, current tissueengineered organs are generally limited to one or two cell layeredconstructs such as skin, cornea, blood vessels, and most recentlyurethras. The cells in these tissue engineered organs are generally notmore than 1-2 millimeters away from the recipient circulation such thatnutrients can reach them by diffusion from the nearby endogenouscapillaries of the recipient.

One known technique used to obtain the expansion of breast tissuewithout prosthesis implant, is called lipofilling and envisages thegraft of adipose tissue (properly treated) into the breast that is to beexpanded. The adipose tissue, after a suitable period (some weeks),gives mature fat cells fully integrated into the pre-existing tissue andmakes the expansion of the breast essentially complete to result in abreast augmentation or a breast reconstruction in the case of amastectomy. Even if the basic mechanism is not completely clear, it issupposed that such fat cells come from the transformation of mesenchymalstem cells present in the treated adipose tissue, favoured by theparticular environmental conditions in which they are. (see G. Rigotti,A. Marchi, M. Galie, G. Baroni, D. Benati, M. Krampera, A. Pasini and A.Sbarbati (2007) “Clinical treatment of radiotherapy tissue damages bylipoaspirates transplant: a healing process mediated by adipose derivedadult stem cells”. Plast Recon Surg. 119(5):1409-22; Rigotti G, MarchiA, Baroni G, Sbarbati A, Delay E, Rietjens M, Coleman S R (2010) “Fatgrafting to the breast: aesthetic and reconstructive applications” Ined. Jones G E. Bostwick's Plastic and Reconstructive Breast Surgery,Third Edition, Quality Medical Publishing, 2010, pp 251-293; e RigottiG, Marchi A, Sbarbati A “Adipose-derived mesenchymal stem cells: past,present and future” Aesthetic Plast Surg. 2009 May; 33(3):271-3. Epub2009 Apr. 21. PMID: 19381713 [PubMed—indexed for MEDLINE].

The treatment of the adipose tissue to be grafted in the involved bodyregion is a known technique: the tissue fat is centrifuged and thefraction containing the vascular-stromal component is actually grafted.Alternatively, the fat harvested by liposuction can be allowed tosediment and the entire supernatant fat suspension used as the graftingmaterial. This approach has several advantages, particularly when thegraft is autologous, that is when the fat is taken from another bodyarea of the patient. This technique makes it possible to obtain theelimination of any problem of rejection. In addition, other problemsrelated to the use of prostheses are avoided, such as the risk offailure of the implant (breakage or other). Besides these advantages,the technique of lipofilling (that is the grafting of fat) has, however,some drawbacks, including the fact that the newly grafted fat tissue,before giving mature adipocytes well integrated into the surroundingtissue, may be at least partially absorbed into the body, reducing theeffectiveness of the tissue expansion induced by the graft.

The inventors observed that this phenomenon is facilitated by thenatural tendency of the expanded tissues to contract elastically torecover their original condition and therefore, have understood the needto support adequately the expanded body region in order to keep it inshape for the time necessary for the grafted adipose tissue to give riseto mature fat cells, that have stably taken root on the pre-existingtissue.

The invention as disclosed herein comprises a method of tissueengineering which is a radical departure from the prevailing wisdom inthe art of trying to build an organ ex-vivo, in the laboratory (or inwhat is commonly referred to a tissue reactor), and then transplant itto the needy host. Also disclosed are several devices for achieving thismethod. The invention finds as one of its main applications in plasticand reconstructive surgery, in particular in the treatments necessary toachieve an increase in the volume of human breast, for example inmammary reconstruction and augmentation mastoplasty, although theinvention has broader applications as well and should not be consideredas limited thereto. For example, the method and devices disclosed hereinalso have application in the treatment of body contour defects, whetherfrom scaring or congenital abnormality. Another application is in theexpansion of solid organs as the expansion generates the scaffold orstromal component and the grafting provides the necessary cellularcomplement (whether obtained by liposuction or other harvesting andtissue culturing methods) required to regenerate the organ.

Previously disclosed in several of a co-inventor's earlier issuedpatents is a novel method and devices for performing the method oftissue engineering whereby the host organism is induced to generatein-situ this vascular stromal scaffold. As this vascular scaffold grows,it induces new blood vessel formation (neoangiogenesis) and derives itsadditional circulation from the host. MRI angiograms demonstrate thatthis method accomplished this tissue engineering crucial effect This isdisclosed and claimed in any one or more of one of the co-inventor'sissued U.S. Pat. Nos. 5,536,233; 5,662,583; 5,676,634; 5,695,445;6,083,912; 6,500,112; 6,514,200; 6,641,527; 6,699,176; 6,730,024; and6,296,667, the disclosures of which are incorporated herein byreference.

External expansion as disclosed and claimed in these earlier patentsachieved this effect by applying an external or “dynamic” orthogonaloutward distractive pull against the surface of the tissues targeted togrow. The preferred methods and devices for achieving this externalforce application at the time was disclosed and claimed in theco-inventor's previous patents mentioned above, which are presentlybeing successfully commercialized as the Brava Bra® device. At present,to the inventors' knowledge, this device is the only FDA reviewedexternal three dimensional tissue expander on the market. The Brava®device applies an external distractive pull on the outer surface of thetargeted soft tissues by means of a controlled and continuous,relatively low, vacuum pressure. Although modifications of the vacuumpressure and intermittent cycling of the pressure to higher levels thatcannot be tolerated for long periods was found to be a more effectivemethod of expanding the organ.

Vacuum applies an isotropic force on the surface of the tissue, and itsoutward pull can be controlled through regulating the amount of negativepressure maintained in the dome shell. However, applying constant vacuumover complex and naturally moving surfaces is a challenge and thenecessary device, while comfortable enough to achieve commercialsuccess, is necessarily more cumbersome and difficult to wear and, whilethe inventors are unaware of any serious issues caused directly orindirectly by the use of this device, it must be acknowledged that itmay, if not properly administered in accordance with the recommendedregimen, exhibit a risk of problems for internal organs and for thesurface upon which the device is applied.

Alternative means of applying a distractive force on an external organsuch as the breast is to mechanically pull on the skin surface bypulling on an intermediate layer mechanically secured to the skin bymeans of an adhesive, or surface tension or sutures, or other mechanicalfastening devices. Various examples of these devices may be found in theco-inventor's patents mentioned above.

In a presently pending U.S. patent application Ser. No. 12/298,011 filedJul. 24, 2009 with a priority claim to Ser. No. 11/409,294 filed Apr.21, 2006, the disclosures of both of which are incorporated herein byreference, there is a method disclosed for generating a tissue scaffoldwith external expansion by applying a vacuum followed by seeding thetissue scaffold with a suspension of fat cells obtained by liposuctionand holding the enlarged expanded grafted space open to allow forsuccessful engraftment. Also disclosed is the step of after, injectingan expanded scaffold with more liposuctioned fluid volume, maintainingthat further enlarged state for a certain period of time so that as thetension dissipates, the tissues stabilize and the graft revascularizesand survives.

Disclosed also is that to achieve this desired effect a Brava® bra-likeexternal expander device could be used, or alternatively, a splint,bandage or other immobilizing device (hereinafter “splint” or “stent”)could be applied that conformed to the new enlarged shape, adhered tothe skin and was rigid enough to prevent any significant recoil,collapse or loss of the surgically engrafted expansion for a period oftime.

As the inventors have continued their inventive activity during thecourse of their surgical practice, they have discovered that a splint orstent was more comfortable to wear than the Brava® device. Furthermore,compared to the Brava® device where wearing of the larger than ordinarybra was required for hours at a time, which translated to less thandesirable patient compliance, a splint which is less cumbersome and morecomfortable to the skin resolves the very important patient complianceissue.

As the patient's expanded scaffold is engrafted with “dilutelipoaspirate”, the injected volume further enlarges the organ (thebreast) and holds it in this enlarged state by means of an adhered, atleast semi-rigid, splint that prevents recoil, this method not onlyhelps the engraftment process, but can also cause further expansion.

As the procedure has been refined, more and more dilute lipoaspirate(more fluid, less fat cells) can be injected and more grafting sessionsthat were smaller in extent (less liposuction required) have been used.In between the grafting sessions, the semi-rigid conforming adherentsplint is more comfortable, less discernible to others, and hence morelikely to be worn than the Brava Bra® device. With this improved method,the need for using the Brava external expansion device between graftingsessions has been obviated, having been replaced by the less intrusivesplint.

In further refining the procedure, to cause the organ to swell, insteadof pulling on the outside for a long sustained period of time asoriginally performed with the external expander devices, physiologicfluid was injected inside the organ alone, without cells. The injectioncaused significant swelling and was limited by the internal tensioninside the organ. In essence, injecting the breast with fluid producedthe same effect as the external expander, i.e. tension in the breast.Left alone, the injected fluid would be expected to be rapidlyreabsorbed by the body thereby simply reversing the expansion andreducing the swelling. Thus the tissue would not ordinarily be expectedto sense any sustained tension that would induce the formation of astromal matrix and recipient scaffold and the desired increase in volumeobtained with the injection would be lost.

While working with the external expander and inflating breasts withphysiologic solutions, the inventors came to the realization that theimmediate application of the splint that retains the swelling maintainsthe sustained tension required for the tissue engineering matrix toform. Within a period of days to weeks, that sustained tension has beenfound to induce the formation of the stromal matrix in as effectivemanner to that of the sustained tension of the Brava external expander.

Internal tissue fibers under tension sense the same forces whether(under the effect of the Brava® device or other dynamic traction device)the skin surface is pulled from the outside or whether the skin is heldup to prevent recoil once the internal tension has already been induced.From a mechanical standpoint the forces required for inflation of thetissue are thought to be approximately the same forces that will beforcing its recoil. The inventors therefore came to the conclusion thatpreventing the recoil of forced internal inflation by holding up theskin (forced inflation and passive splinting) achieves the samephysiologic effect as pulling up on the skin to force its inflation(external dynamic expansion).

Interestingly, patients subjected to both modalities confirmedexperiencing the same sensation.

While inflation is ideally diffuse if the inflating agent is placedthroughout the tissue and within all tissue planes, it is also effectiveif the inflating agent is placed only in localized areas and we allowfor natural diffusion of the injected material through osmotic forcesand mechanical gradients of tissue compliance amongst the tissue typesand the tissue planes. With respect to cellular agents injected into thetissue, such as fat, stem cells or the like, in order to achieve thebest results with minimal necrosis, it has been found that diffuseinjection of the inflating agent is preferred. For inflating agents thatare acellular, such as saline, suspensions of particulate matters suchas tissue matrix agents, or gels and other physiologically compatiblefluids such as maybe even air (which has not yet been tried by theinventors but is conceived as eligible for use), it has been found thatoptimum results are not as dependent on a diffuse inflation.

The description above discusses inflating the soft tissue throughinjection of a physiologically compatible agent or fluid. Whileinjection has been used by the inventors with success, the inventorsconceive that the soft tissue can also be inflated through other meansthat can apply a distractive force to the tissues. One such example isto induce acute edema to the tissue and then while the tissue isexpanded rapidly apply a passive stent. Using the breast as an example,a high pressure pump may be used to create a temporarily strongdistractive force in cups applied to one or both of the breasts atpressures above what can be physiologically tolerated for more than afew minutes and then recycling after a few minutes rest giving time forthe tissue to recover to achieve the desirable augmentation, remove thecups, and then apply passive stents to the breasts which are suitablefor being comfortably and unobtrusively worn for some extended timeperiod. Depending on the particular construction of the stent, and itsease of application (and expense), the inventors conceive that a patientcould herself replace the stent to allow for personal hygiene, or returnto the Doctor's office for another round of inflation and then anotherset of stents larger than the previous ones. In this way, the patientcan take a stepwise expansion of her breasts until the desired size hasbeen reached.

In yet another modality, the inventors are well aware of a low pressurebra-like device made and sold by Brava, LLC as one of the co-inventorsis the inventor of that device. One of the issues which interferes withpatient success in using the Brava Bra® is that of patient compliance.Although many patients are quite successful and are very happy with theresults achieved with the Brava Bra®, some patients are not as diligentin their wearing of it as while it is remarkably slim and unobtrusive,it is yet more so than a thin bra cup. Furthermore, the recommended weartimes are less than 24 hours a day, which gives the breast time torecoil and then when the Brava Bra® is reapplied, the starting size isless than when it was removed. The present invention of a passive stentmay be coupled for use with the Brava Bra® in order to prevent breastrecoil and thereby accelerate the augmentation process. Simply put, useof the passive stent for those times when the Brava Bra® is not worntransforms a sawtooth pattern into a stepwise expansion pattern ofaugmentation.

It is also contemplated by the inventors that the repeated inflation ordistension of the soft tissue (breast as used for exemplary purposesonly) may be achieved through a mixing of these various methods. Inother words, the first inflation may be achieved through the creation ofan edema or injection in the Doctor's office and subsequent inflationscould be achieved through use of a low pressure or higher pressurecycling vacuum pump at home by the patient. It is also conceived by theinventors that a “kit” for home use could be put together comprising thepresently commercially available Brava Bra® and vacuum pumps and a setof passive stents which the patient could self-apply during theintervals when not wearing the Brava Bra®.

In sum, the present invention is expected to be able to be used tomaximize expected results through use of the Brava Bra® in soft tissueaugmentation without surgical intervention or even injection.

When the patient returns back to the office, a few days to a few weeksafter inflation, the splint is removed and the inventors have found thatthe organ (breast) has substantially maintained the operativeenlargement due in large part to the adherent splint that preventedtissue recoil. However, while immediately after injection the breast wasinitially tight and fir n from the large injection volume, it has beenfound after the passage of time to be soft and loose as the tissues hadinternally and externally stretched and expanded to accommodate thetension. In this regard, the physiologic process of tissue expansion hasbeen found to be essentially similar to the dynamic external expanders.

With the enlarged (organ) breast now soft again, additional physiologicfluid may then be injected, enlarging it more until it becomes tight andfirm again. A new splint may then be applied so that it conforms to thenewly enlarged expanded state and the patient is then free to return totheir normal activities, wearing this rigid splint as an adherent bracup for the few days to weeks as required for the tension to equilibrateas the tissues expand further.

The process may then be repeated a few times until the desired recipientscaffold size is reached. At that point, the graft is diffuselydispersed inside the expanded scaffold and a new splint is applied toallow the grafts to revascularize and successfully engraft to regeneratethe deficient organ.

Alternatively, this process of physiologic solution injection to expandthe tissues followed by passive splinting to maintain the expanded statecan be serially repeated until mechano-transduction, the process throughwhich tissues grow in response to sustained mechanical expansion,generates enough tissue to obviate the need for tissue grafting. Inessence, the inventors discovered a new method of tissue expansionwhich, in effect is an alternative to the devices described in previouspatents and patent applications.

It is thus one aspect of the present invention to create a physicalstructure to he applied to a body area subject to tissue expansion,which is structurally and functionally designed to overcome thelimitations described above with reference to the cited state of theart. In this regard, one function of the invention is to provide adevice for maintaining morphology of a soft tissue site or organ, i.e.that is able to maintain the shape and volume of the body area subjectto expansion, and to counteract any natural tendency to contract by theinvolved tissues.

Another desirable feature of a preferred embodiment of the invention isto provide such a device that is immediately usable in a post-operativephase and which also exhibits a high biocompatibility with the skin, inorder to permit it to be safely and comfortably worn for a period of 2-3weeks. Yet another desirable feature of a preferred embodiment of theinvention is to provide such a device that is lightweight and easy tocarry, in order to encourage its being worn by the patient during normaldaily activities and thus improve patient compliance. Still anotherdesirable feature of a preferred embodiment of the invention is toprovide such a device that is readily customizable (malleable) so as tobe able to more fully adapt to the shape of the body area of theindividual patient. Yet another desirable feature of a preferredembodiment of the invention is to provide such a device that is easy toapply to the involved body area and, if necessary, just as easy toreplace.

The invention also comprises a kit that can contain a device to distendthe breast, such as a vacuum pump of the Brava modality or a highpressure pump, one or more breast cups to be applied to the breast toachieve the distention, and one or more passive splints which couldpotentially be applied over several weeks by the patient herself.

It will be apparent to any person of ordinary skill in the art ofsurgical reconstruction that one of the invention's preferredembodiments comprising the splint to be applied over the breast (organ)can be embodied in a multitude of designs using a large variety ofmaterials.

The common requirement however to these are as follows:

Important attributes:

a. adheres firmly to the skin or the surface of the organ to preventrecoil and detachment during the patient's regular activities.

b. can be conformed to match and cover the exact shape and contour ofthe swollen breast or organ.

c. while malleable when first applied, it should rapidly harden espousethe desired shape.

d. in the hardened state have mechanical properties that can counteractthe tissue recoil.

e. be bio-compatible and capable of being tolerated for long termapplication (1-3 weeks of uninterrupted wear). The splint isconveniently adapted to be made out of many bio-compatible “breathablematerials” as known in the art.

Desirable attributes:

a. easy to apply kit

b. comfortable (semi-rigid, that is while preventing collapse, rubberlike to allow for some bending, as compared to rock hard plastic)

c. thin (one Inch or less)

d. skin colored

e. smooth contours that blend and taper with the chest wall skin

f. have the appearance of a stick on, well camouflaged external breastprosthesis.

g. items b-f should render the device easy to conceal and to wear 24/7.

h. transparent or translucent so the underlying skin can be monitored,both to ensure that the splint is in good adhesive contact at the timeof application and that any rash or irritation can be readily detected.

Another way of mechanically coupling the splint to the skin is surfacetension. Surface tension is the naturally occurring means by which thebody holds together tissues that need to remain mechanically coupled butyet glide and avoid shear forces. This is how the expanding rib cagetransmits the mechanical force of inhalation to the soft sponge likelungs to expand and this is how bowel loops can glide past another whileheld together too.

The external splint can be akin to a swim cap or to a toilet plungerpump. Semi-rigid, conforming and with a film layer of surface tensionthat transmits the mechanical recoil of the plunger rubber to the skinsurface and pull it outward.

The many embodiments of this splint embodiment (or adherent semi-rigid,conforming bra cup) that can be applied over an organ swelled up andtensed up by injection include but are not limited to:

A. Single layer embodiment:

Here a spray, paint, or putty form of a soft rubber or a rubber sheet isapplied over the surface of the organ and that material cures to becomerigid enough to prevent recoil. It could be adherent by itself or mightrequire the addition of an adhesive glue such as a biologicallytolerated adhesive or use surface tension. It might include imbedded orsubsequently applied reinforcing fibers that contribute to the desiredmechanical characteristics.

Specific embodiments would include:

1. The hair spray like device: an aerosol delivered spray of aplastifying material that can coat the surface of the organ and rapidlydry or cure to become an exoskeleton-like shell structure that is hardenough to prevent the forces of recoil. This might be achieved by amodification of the current colloid dressing solutions or the liquidband aids or the cyanocarylate glues used for wound closure or otherbiocompatible polymers that can offer the desired characteristics.

2. Materials similar to the above, instead of being sprayed could bepainted or smeared over the surface of the organ where they wouldrapidly cure to become a hard shell that espouses its exact swollencontour and prevents it from recoiling. A solvent can then be used toremove it when needed.

3. A putty-like soft rubber that can be spread over the surface and madeto cure and become hard either with a catalyst or on air contact or byvarying the temperature or by UV light exposure. The material can bedelivered as sheets that are inherently tacky and stick to the surfacewhen applied, or that need a priming sticky layer like a tissue glue tobe applied first and then the confirming rubber putty adheres to thatglue. Examples of these materials include the cyanoacrylates, epoxy,acrylic, urethane or other polymers such as silicone based medicaladhesive glues.

4. A sheet of adhesive tape like material. This can be either a texturedor fibrous material or it can be a foamy or porous material that istaped over the surface of the organ. There are many well-toleratedpressure sensitive adhesive compounds that can provide a firm adhesionbetween that tape or sheet and the skin. The adhered sheet or tape canthen become hard either because of its inherent ability to cure onexposure to air or water or with the help of a catalyst, temperaturechanges or UV exposure. The device would be supplied in an air tightpouch ready to be applied and would cure either by itself on exposure toair or water, or with the help of the necessary catalyst. Alternatively,the device can be made to harden by painting it, spraying it or addingto it a plastic, rubber, fiberglass, epoxy, urethane or otherbiocompatible polymer, even a plaster of Paris like material.

B. Two layered embodiment: First apply over the breast or the organ alayer of material that will adhere to the skin or to the surface of theorgan to be enlarged. This must be a material known to be well toleratedfor prolonged surface contact (this can range from adhesive tape tohydrogels and hydrocoloids, to cyanocarylates and other liquids or gelsthat stick to the tissue surface). Then add to this another layer of amaterial that can be made to adhere to the first layer, be malleable toprecisely espouse the contour of the swollen organ, and that can be madeto cure and become rigid in this new shape and form (this can range fromthermoplastics to fiberglass like tape to plastics that can be cured onair or water contact or with the help of curing agents, catalysts, ortemperature or light, to rubbers and other biocompatibie polymers suchas silicone and/or polyurethane and their related products andderivatives.

Specific embodiments would include:

1. an adhesive hydrogel for the first layer and then glued and stuck toit.

-   -   a. a thermoplastic material added for rigidity and made to        adhere to the hydrogel.    -   b. fiberglass like material added for rigidity and made to        adhere to the hydrogel.    -   c. plaster of Paris-like material added for rigidity and made to        adhere to the hydrogel.    -   d. a natural or synthetic polymer or their derivatives capable        of adhering to the hydrogel and be malleable enough in the first        state to conform to the surface contour and become rigid in the        second state to prevent recoil.

2. An adhesive silicone gel for the first layer and a rigidifyingsilicone putty adhered to it for the second layer. That putty mightcontain a fibrous mesh as a rigidifying framework.

3. An adhesive foam for the first layer and then glued or stuck to it:

-   -   a. a thermoplastic material added for rigidity and made to        adhere to the foam    -   b. fiberglass like material added for rigidity and made to        adhere to the foam.    -   c. plaster of Paris-like material added for rigidity and made to        adhere to the foam.    -   d. a natural or synthetic polymer or their derivatives capable        of adhering to the foam and be malleable enough in the first        state to conform to the surface contour and become rigid in the        second state to prevent recoil.

4. An adhesive biocompatible sheet like Tagaderm® or OpSite® or a wovenor knitted material similar to the Second Skin.

-   -   a. a thermoplastic material added for rigidity and made to        adhere to the breathable material adherent to the skin.    -   b. fiberglass like material added for rigidity and made to        adhere to the breathable material adherent to the skin.    -   c. plaster of Paris-like material added for rigidity and made to        adhere to the breathable material adherent to the skin.    -   d. a natural or synthetic polymer or their derivatives capable        of adhering to the breathable material adherent to the skin and        be malleable enough in the first state to conform to the surface        contour and become rigid in the second state to prevent recoil.

Anyone of ordinary skill in the art, given the teaching herein, can alsounderstand that in 1-4 above, the first layer that is conforming,biocompatible and adhesive can be subsequently made rigid by adding toit chemical compounds that can provide it with the desired mechanicalrigidity.

5. Biocompatible Materials that can be used:

Natural polymers and their derivatives such as Nitrocellulose, Chitin,etc.

Synthetic polymers such as polycarbon, polyvinyl, polyurethane,polyesther, silicone, and their derivatives.

C. Multiple layer sandwich: First an adherent layer (same range ofmaterials as above) then a rigidifying layer (same range of materials asabove), then a final layer that camouflages the entire construct.

The disclosed invention may also be used for a method of threedimensional tissue expansion.

In conventional tissue expansion, inflatable silicone shells aresurgically inserted and after the surgical wound heals, the expander isserially filled with physiologic fluid to distend it. ultiple fillingsessions a few days to a few weeks apart compress the interveningtissues between the skin surface and the expander shell and only expandthe surface envelope. When removed these expanders then leave behind acavity, a dead space that needs to be collapsed if the expansion is usedfor tissue coverage or in the case of breast reconstruction replacedwith an inert foreign material implant.

With the present invention of tissue expansion, there is no surgicalintervention required to insert any device. By simply injecting aphysiologic fluid inside the organ to be augmented, by inducing anedema, or otherwise mechanically deforming it, not only is the envelopegenerated and stretched, but what does occur is that a stromal threedimensional recipient matrix for tissue engineering is also generated.As with conventional expansion, the quantity injected is limited by thelevel of tissue tension that can be tolerated and repeated injectionsare preferably needed a few days to weeks apart, or once the tissuesexpand and become lax again to become eligible for further injections.However, while with the internal expanders tension is maintained by thedistended shell that compresses the underlying tissue and only stretchesthe outer envelope, with the present invention the tension on thetissues is generated by the application of an external shell thatprevents collapse and uniformly distributes the tension to all thetissues contacting the splint to induce their uniform expansion. Withthe present invention using the splint, no surgery is required, nocomplication can result from foreign material being inserted, no tissuecompression at all. Only diffuse generalized internal expansion forces(tension) are created, which have been found to be adequate to achievethe desired effect.

Other examples of suitable injectable materials range from simplephysiologic electrolyte solutions to dilute suspension of specializedcells, to solutions containing growth promoting agents, or tosuspensions and solutions of tissue matrix components that mightaltogether obviate the need for the cell seeding step as the improvedinjectate stimulates not only stromal matrix formation but also theproliferation of cells required to populate the organ.

As for the preferred embodiment, the inventors continue to search fornew materials which satisfy both the important as well as the desirableattributes. However, at the time of filing, the inventors havesuccessfully used the process of applying a layer of surgical tape,microfoam or hypofix type, and added on top a layer of fiberglassmaterial customarily used to make fracture casts. While it is stillmalleable, the fiberglass plastic can be made to stick to the tape whileit rapidly cures into a hard shell (like a cast) that espouses thecontour of the expanded breast. This hard cup bra-like splint thenremains adhered to the tape which is itself adhered to the skin. If wellapplied, the inventors have found that this construction will hold for aweek, however the inventors would prefer other materials that wouldexhibit a longer life. This construction results in a somewhatcumbersome device but does have the advantage of being made out of offthe shelf materials routinely available to any surgeon.

While not to be considered as limiting in any way, or as fully andcompletely defining the scope of the inventions disclosed herein, theinventors shall further exemplify the invention through the illustrativedescription and drawings depicting the preferred embodiments,

Definitions

It should be noted that in the present description and following claims,an element will be called “deformable” or “malleable” if its shape canbe changed even under the effect of negligible forces, such as thoseexpressed by a simple manipulation of an operator, particularly when itcan be manually morphed to the shape of a human breast or other organ orother contour defect in need of correction. Malleable would include amoldable or shapeable sheet of material or sheets of material such asfiberglass or plaster of Paris impregnated cloth which is initiallyshapeless and adopts the morphology of the body tissue to which it maybe closely applied. In addition, an element will be called “rigid” or“semi-rigid” when it will not deform significantly due to typicalstresses caused by morphological forces such as the natural contractionof a distended breast, which is expanded by for example injecting aphysiologically compatible fluid, inducing an edema such as by applyingand cycling a high pressure vacuum to the breast, by applying acontinuous low pressure vacuum over time (such as under pressuresrecommended for use with the Brava Bra®), etc. Furthermore, in thedescription and subsequent claims, the deformation of an element will becalled “not appreciable”, when, conformed to the shape of the tissuedesired to be enlarged, such as by having the shape of a cup similar toa human breast, and undergoing a load of radial compression, produces anot meaningful volumetric shrinkage which materially detracts fromachieving the desired tissue expansion.

As used herein, the term “physiologically compatible agent” or“physiologically compatible fluid” should be understood as includingboth “cellular agents” or “cellular fluids” such as stem cells and fat,as well as “acellular agents” or “acellular fluids” such as saline,gels, air, etc. Cellular agents or cellular fluids are understood as anagent or fluid that principally comprises cells, stem cells, harvestedcells, genetically manipulated cells, cultured cells or the like.Acellular agents or fluids are understood as comprising gels,suspensions or solutions such as saline, chemicals that might promotegrowth or satabilization or tissue health, biologic tissue promoters ortissue substitutes, tissue inductive material, tissue matrices, etc.

As used herein, and elsewhere, the words “splint” and “stent” are usedinterchangeably but both can be defined as a deformable or moldabledevice intended to be shaped to be in intimate contact with the skin orother soft tissue surface and which maintains the morphology of thesurrounding and underlying tissues. The word “splint” is generallyconsidered as being relatively rigid in orthopedic uses while a “stent”is generally considered as being deformable or moldable to more closelyfollow the contours of the surface in question. The desirable propertiesof the stent air splint as described herein characterize the devicebeing referred to so as to enable those of ordinary skill in the art tounderstand this reference.

The term “passive splint” or “passive stent” or “splint” or “stent” asused herein shall be understood as meaning a device which does not applyan external force to any underlying tissue to which it might be adhered,other than to resist the natural morphological forces which seek toreturn soft tissue to its previous relaxed or natural state. It is to becontrasted with what might be referred to as a “dynamic” forceapplication device, such as a vacuum pump, which has the capability toapply an external force to body tissue.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a cross-sectional view of a first embodiment of the inventioncomprising a stent or dome applied to a breast previously subjected totissue expansion;

FIG. 2 is a perspective view of a sheet shaped adhesive element to beadhered to the breast and conform to its shape;

FIG. 3: is a perspective view of a second sheet of material, adhered tothe first and adjustable between deformable and rigid in character;

FIG. 4 is a cross-sectional view of a second embodiment of theinvention, applied to a breast subject to tissue expansion;

FIG. 5 is a cross-sectional view of another embodiment of the inventioncomprising what can be a single or multiple layer splint, applied to abreast;

FIG. 6 is a perspective view of another embodiment of the inventioncomprising a malleable sheet;

FIG. 7 is a perspective view of yet another embodiment of the inventioncomprising a malleable sheet which may be woven or reinforced;

FIG. 8 is a perspective view of yet another embodiment of a splint thatmay be pre-formed in the approximate shape of a breast;

FIG. 9 is a perspective view of a vacuum pump connected to a bra cup forinducing an edema to thereby distend the breast;

FIG. 10 is a perspective view of yet another embodiment of the inventioncomprising a splint formed in an approximate circular pattern with aslit for being folded over onto itself and creating an approximate coneshape; and

FIG. 11 is a perspective view of the cone-shaped splint formed with thecircular shaped splint shown in FIG. 10.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

With reference to FIGS. 1 to 3, the first embodiment is generallyreferred to as 1. The device (1) is intended to be applied to the softtissue body area subject to tissue expansion. In this instance, and forillustrative purposes only, the body area consists of a breast (2) whosevolume was increased, preferably by injecting a physiologicallycompatible fluid such as saline, or less preferably by grafting properlytreated autologous adipose tissue, in each instance optionally precededby a period of treatment of vacuum or mechanical stimulation.Nevertheless it is understood that the present invention can be appliedin the same way in any surgery, aimed at changing the congenital oracquired body profile through fluid injection or adipose tissue graft,such as in the treatment of depressions caused by scars, surgicalresections or malformations. The device is not only limited to externalskin surfaces but can also be applied to internal defects and to solidorgans.

The device (1) preferably includes a sheet-like layer of an adhesiveelement (3), which is preferably made from materials that are easilydeformed even at room temperature (about 25° C.) and able to adapt tothe widely varying shapes and sizes of the female breast (2). Theadhesive element (3) is preferably sheet-shaped, and includes, incorrespondence of its outer surface (3 a), an adhesive layer (4) thatmay be applied directly on the skin surface of the breast (2), and abacking layer (5) superimposed to the adhesive layer (4). Both layers(4) and (5) may preferably have a thickness between about 0.5 and 3 mm.The adhesive layer (4) is preferably an hydrocolloid, with highbiocompatibility with the skin, so to ensure that the device (1) can besafely and comfortably applied to, and worn on, the breast (2) forreasonably lengthy periods of time, if necessary, without needingreplacement. In addition, the biocompatibility of the adhesive layer (4)allows its application on the skin immediately after the surgical breastexpansion, even in the presence of post-operative edema which istypically present after these surgical interventions.

The backing layer (5) is preferably made of soft polymer material, e.g.thermoplastic polyurethane based foam or other polymeric material withsimilar characteristics of softness and deformability. In this way, theadhesive element (3) can adhere completely to the skin surface of thebreast (2), adapting virtually perfectly to its shape. The adhesiveelements described above may be provided for example by the companyConvatec under the trade name of DuoDerm®.

The device (1) also preferably includes a structural element (10)coupled to the opposite side of the adhesive layer (4). Even thestructural element (10), like the adhesive element (3), is preferablysheet-shaped, with a thickness preferably between 0.5 and 4 mm. Thestructural element (10) is preferably basically rigid at roomtemperature, so that it does not deform significantly when subjected tostresses caused by the natural contraction of the body area involved inthe tissue expansion. In particular, the structural element (10), atroom temperature, is preferably able to resist without deformingsignificantly when loaded by the natural contraction of the expandedsoft tissue, such as the breast (2), following tissue expansion and,among other factors arising from the tissue elasticity and from thepost-operative reabsorption of the edema. The material preferably usedfor the structural element (10) exhibits a high chemical compatibilitywith the material used for the backing layer (5) of the adhesive element(3), so that it can ensure an effective adhesion to it, even withoutadditional layers of glue. However, it is optionally envisaged that anadditional adhesive layer can be applied between the two elements 3 and10, for example a cyanoacrylate-based material indicated for medicaluse. Most preferably, the structural element (10) is made ofthermoplastic polymer having properties such that when heated to atemperature between 50° and 80° C. (at first instance comparable to themelting point of the polymer), it softens in such a way to be easilydeformed by a surgeon's manual manipulation. In this way, the structuralelement (10) can be stretched over the adhesive element (3), be adaptedperfectly to the shape of the breast (2) and maintain this conformation.

Thermoplastic polymer materials softening at temperatures above 80° C.are not presently considered suitable for use in the present invention,because they would be too hot to be manipulated by a surgeon or to beused on a patient, even in overlap with the adhesive layer (3). On theother hand, thermoplastic polymer materials softening at temperaturesbelow 50° C. are not presently considered suitable for use in thepresent invention, because they would not have adequate stiffness atroom temperature or at temperatures between 35 and 40° C., easilyaccessible in many countries in summer. Preferably, the structuralelement (10) is made of a polymer based on polyeaprolactone, coveredwith a layer of urethane acrylates. Several holes with a diameterranging between 3 and 5 mm are made preferably on the structural element(10) and placed regularly on its surface. These holes (11) allow aneasier deformation of the structural element (10) when brought totemperatures between 50 and 80° C., allowing at the same time a decreaseof the mass of the structural element (10), in order to be lighter andto provide faster and more even temperature changes both in the heatingand the cooling phases.

The use of this preferred embodiment takes place as described below, atthe end of the treatment of tissue expansion of the soft tissue,preferably obtained through the injection of physiologically compatiblefluid or grafting of properly treated autologous fat tissue. In thefirst phase, the adhesive element (3) is carefully laid on the expandedbreast (2) to adhere perfectly to the skin surface. After that, thestructural element (10) is heated at a temperature between 50 and 80° C.so that the surgeon can easily deform it and lay it on the adhesiveelement (3) previously applied to the breast (2), adapting to itsmorphological conformation. The preferable chemical compatibilitybetween the adhesive element (3) and the structural element (10) permitstheir mutual adhesion. Both the adhesive element (3) and the structuralelement (10) are laid to cover the entire area involved in the tissueexpansion, including preferably a considerable margin around it. Thestructural element (10) cools rapidly to room temperature, making itstiff enough to hinder effectively the natural tendency to contract ofthe expanded tissue.

The sizing and the material of the structural element (10) are such thatthe cooling takes place as quickly as possible, but long enough toprovide the surgeon with the time necessary to lay the structuralelement on the adhesive element (3). After the application of thestructural element (10) and its cooling, the device (1) can be left onthe breast (2) for a long period, even weeks if considered desirable, topromote the development of mature fat cells and their integration intothe pre-existing tissue. If necessary, the device (1) can be replaced,by detaching the adhesive layer (4) from the breast (2) and repeatingthe steps described above with a new adhesive element and a newstructural element. The device of the present invention is verylightweight and easy to wear, without causing discomfort or pain in thebody region around the expanded tissue (breast). In fact, the pressurescaused by the tissue's natural contraction is very low, in particular ifcompared with those necessary to stimulate its expansion by vacuumapplication as in the known devices. In addition the device of thepresent invention is customizable, as it is adaptable to the morphologyof the specific patient. A further advantage of this invention is thatits application promotes a biological response, which is thought to leadto the transformation of the stem cells present in the treated andgrafted adipose tissue into mature adipocytes. The structural element(10), before being used, can be provided in the form of a flat sheet orin a convenient alternative, already preformed cup according todifferent predefined sizes.

With reference to FIG. 4, another embodiment of the invention is shownand referred to generally as 100 therein. The device 100 differs fromdevice 1 described above by incorporating an additional element withvariable thickness 101, interposed between the adhesive element (3) andthe structural element (10). The function of this element with variablethickness (101) is to improve the adaptability of the structural element(10) to the morphology of the expanded body region through a controlledreduction of its volume and thickness.

The element (101) designed with variable thickness is preferably made ofpolymer foam, e.g, polyurethane, whose radial thickness is adjusted byaspiration of the air contained in it.

Yet another embodiment 120 is depicted in FIG. 5 and includes withinthis single drawing figure a number of alternative constructions. Forexample, there is depicted a stent 122 which has been adhered to abreast with an adhesive layer 124. Stent 122 could have the layer 124 ofadhesive applied to its inner surface 126, or the adhesive could beapplied separately such as by being sprayed on or as being part of adouble-sided, adhesive coated tape 124. Layer 124 could be a layer ofgel or silicone and if necessary an additional layer of adhesive couldbe applied. Layer 124 could also be a layer of second skin. The singlelayer stent 122 could be formed from a sheet of material (see FIGS. 6 &7) such as a thermoplastic material, natural or synthetic polymer orfrom multiple sheets of overlapping material which cures into a rigidconstruction, like fiberglass or plaster of Paris as might be used for acast, for example. Stent 122 could also be applied like a putty, such assilicone. There are many other materials, as known to those of skill inthe art which could be substituted for these exemplary materials, usingthe teaching and guidance of the present disclosure.

As shown in FIG. 6, the stent 122 may be a single sheet of materialbefore application to the soft tissue site; flexible for being readilyconformed to the soft tissue site and then being capable of becomingrigid to maintain the morphology of the site. For example, such aflexible single sheet of material 122 may be sized to adequately coverthe breast and as explained above have one of its surfaces covered withadhesive or not. As shown in FIG. 7, the stent 122 may be woven orreinforced which can make it both easier to pre-mold into shape and alsobetter hold its molded shape after it is cured or otherwise transformedinto a rigid structure adhering to the breast. FIG. 8 depicts yetanother representative shape for the stent 122. As shown therein, thestent 122 may be pre-molded into somewhat the shape of different breastcup sizes to minimize the possible introduction of wrinkles as the stent122 is manipulated around the breast. Also, optionally, a flattened edgesurface 126 to help form a seal at the edge of the stent 122 against thepatient's chest.

As shown in FIG. 9, a Brava Bra® system 128 may include a breast cup 130adhered around a breast and held in place by a vacuum created betweenthem by a pump 132. The periphery may also have an adhesive applied tohelp hold it in place during wearing. Pump 132 could be either a lowpressure pump for continuous use in accordance with the recommendedprotocol, or a higher pressure pump for recycling as explained above todistend the breast.

As shown in FIG. 10, the splint or stent 122 may be pre-formed in anapproximately circular shape with a slit 134 to facilitate its beingfolded or collapsed around itself and thereby form the cone shape shownin FIG. 11.

The methods of use of the various inventions disclosed herein have beenexplained above as would be readily understood by those of skill in theart.

The invention has been illustrated through its preferred embodiments asshown in the drawing figures and as described in the description above.These preferred embodiments are not intended to be limiting in any way.Instead, the invention is intended to be limited solely by the scope ofthe claims appended hereto and their equivalents.

1-43. (canceled)
 44. A method for augmenting a region of soft tissue ina subject, the method comprising: swelling the region of soft tissue byapplying a distractive force and/or injecting one or more inflatingagents into the region; and applying one or more splints to the surfaceof the swollen soft tissue for an amount of time sufficient to form astromal matrix within the swollen soft tissue.
 45. The method of claim44, wherein the one or more inflating agents comprise a saline solution,air, a suspension of tissue matrix agents, a suspension of gels, dilutelipoaspirate, or a combination thereof.
 46. The method of claim 44,wherein the stromal matrix comprises a recipient scaffold.
 47. Themethod of claim 46, further comprising dispersing a material derivedfrom fat into the recipient scaffold.
 48. The method of claim 46,further comprising dispersing an adipogenic material into the recipientscaffold.
 49. The method of claim 44, further comprising: furtherswelling the region of soft tissue after applying the one or moresplints by further injecting the one or more inflating agents in theregion; and applying one or more further splints to the surface of thefurther swollen soft tissue.
 50. The method of claim 49, wherein thefurther swelling and application of one or more further splints isperformed periodically until tension is reduced in the soft tissue. 51.The method of claim 44, wherein the one or more splints comprise atleast one layer configured to adhere to the surface of the swollentissue.
 52. The method of claim 51, wherein the at least one layer isconfigured to adhere to the surface of the swollen soft tissue bysurface tension.
 53. The method of claim 51, wherein the at least onelayer comprises a rigidifying structure.
 54. The method of claim 51,wherein the at least one layer comprises a material configured to becomerigid or semi-rigid upon curing.
 55. The method of claim 53, wherein theone or more splints comprise two layers.
 56. The method of claim 44,wherein the one or more inflating agents comprise fat, stem cells, cellsderived from fat, an adipogenic agent, a material derived from fat, or acombination thereof.
 57. A method of breast augmentation and/orreconstruction in a subject, comprising: swelling the breast by applyinga distractive force and/or injecting one or more inflating agents intothe breast; and then applying one or more splints to the surface of theswollen breast to preserve the swelling.
 58. The method of claim 57,wherein the one or more inflating agents comprise a saline solution,air, a suspension of tissue matrix agents, a suspension of gels, dilutelipoaspirate, or a combination thereof.
 59. The method of claim 57,wherein the one or more inflating agents comprise fat, stem cells, cellsderived from fat, an adipogenic agent, a material derived from fat, or acombination thereof.
 60. The method of claim 57, further comprisingdispersing a material derived from fat or an adipogenic material intothe swollen breast.
 61. A method for augmenting a region of soft tissuein a subject, the method comprising: swelling the region of soft tissueby applying a distractive force and/or injecting one or more inflatingagents into the region; and applying one or more splints to the regionof soft tissue; wherein the one or more inflating agents comprise fat,stem cells, fat cells, cells derived from fat, an adipogenic agent, amaterial derived from fat, or a combination thereof.
 62. The method ofclaim 61, further comprising: further swelling the region of soft tissueafter applying the one or more splints by further injecting the one ormore inflating agents in the region; and applying one or more furthersplints to the surface of the further swollen soft tissue.
 63. Themethod of claim 62, wherein the further swelling and application of oneor more further splints is performed periodically until tension isreduced in the soft tissue.